The metabolic syndrome and cardiometabolic comorbidities of psoriasis
Authors:
Karolína Vorčáková; Tatiana Péčová; Juraj Péč
Authors‘ workplace:
Dermatovenerologická klinika LF UK v Martine
Published in:
Forum Diab 2016; 5(1): 50-54
Category:
Topic
Overview
Chronic plaque psoriasis is a chronic erythematosquamous disease which affects 2–3 % of the population. In the etiopathogenesis of moderate to severe psoriasis a large amount of proinflammatory cytokines (TNF alpha, IL6, IL17, IL20, IL23) is produced which then affect other organs and results in chronic systemic inflammation. Moderate to severe psoriasis is more frequently associated with cardiometabolic comorbidities the most significant of which is the metabolic syndrome. Etiopathogenesis of psoriasis is linked to that of the metabolic syndrome. The diseases have a common genetic basis and produce mutually stimulating cytokines. The whole cycle of proinflammatory cytokines contributes to a higher cardiovascular risk, mainly in young patients with severe disorders. Early commencement of systemic and biological treatment of psoriasis, education and rigorous evaluation of patients’ comorbidities can prevent development of the metabolic syndrome and increased cardiovascular risk.
Key words:
biological treatment – cardiovascular risk – metabolic syndrome – psoriasis
Sources
1. Lotti T, Hercogová J, Prignano F. The concept of psoriatic disease: cancutaneous psoriasis any longer beseparated by the systemic comorbidities? Dermatol Ther 2010; 23(2): 119–122.
2. Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163(3): 586–592.
3. Mc Donald CJ, Calabresi P. Psoriasis and occlusive vasculardisease. In Br J Dermatol 1978; 99(5): 469–475.
4. Galajda P, Mokáň M. Problematika etiopatogenézy a diagnostiky metabolického syndrómu. Diabetes a obezita 2004; 4(7): 39–49.
5. Alberti KG, Zimmet P, Shaw J (IDF Epidemiology Task Force Consensus Group). The metabolic syndrome a new worldwide definition. Lancet 2005; 366(9491): 1059–1062.
6. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68(4): 654–662.
7. Langan SM, Seminara NM, Shin DB et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132(3 Pt 1): 556–562.
8. Martinásková K Jr. Chronická ložisková psoriáza, jej vzťah ku komorbiditám a HLA-Cw6 u pacientov liečených antagonistami TNF-alfa (adalimumabom a etanerceptom). Dizertačná práca. Univerzita Komenského v Bratislave: Martin 2012.
9. Sales R, Torres T. Psoriasis and metabolic syndrome. Acta Dermatovenerol Croat 2014; 22(3): 169–174.
10. Voiculescu VM, Lupu M, Papagheorghe L et al. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications. J Med Life 2014; 7(4): 468–471.
11. Paller AS, Mercy K, Kwasny MJ et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol 2013; 149(2):166–176.
12. Eckel RH, Grundy SM., Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415–1428.
13. Gisondi P, Targher G, Zoppini G et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51(4): 758–764.
14. Gisondi P. Cardio-metabolic comorbidities of psoriasis. Clin Dermatol 2013; 2(2): 116–119. Dostupné z WWW: <http://www.clinicaldermatology.eu/materiale_cic/697_1_2/6022_cardio/article.htm>.
15. Yiu KH, Yeung CK, Chan HT et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164(3): 514–520.
16. Jensen PR, Zachariae C, Hansen P et al. Normal endothelial function in patients with mild-to-moderate psoriasis: a case-control study. Acta Derm Venereol 2011; 91(5): 516–520.
17. Boehncke S, Fichtlscherer S, Salgo R et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2011; 303(6): 381–388.
18. Greenberg JD, Kremer JM, Curtis JR et al. Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4): 576–582.
19. Hugh J, Van Voorhees AS, Nijhawan RI et al. 2014. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014; 70(1):168–177.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
![Issue 1](https://www.forumdiabetologicum.sk/media/cache/resolve/journal_issue/media/image_pdf/abcc521b121f74722af2a2d608f92040.jpeg)
2016 Issue 1
Most read in this issue
- New drugs in the treatment of obesity: their availability for clinical practice
- GLP1-analogs – suitable choice in obese patients with type 2 diabetes mellitus
- Nonalcoholic fatty liver disease – a serious comorbidity of diabesis
- Metabolic changes after bariatric/metabolic operations